ACSQHC-ARCR-373

Although surgery is the standard of care for primary renal cell carcinoma (RCC), many patients in this population have comorbidities that may preclude them from having the necessary procedure.

The International Radiosurgery Oncology Consortium for Kidney (IROCK) will collect high quality, prospective data from patients who undergo stereotactic ablative radiotherapy (SABR) for primary RCC. The primary purpose of the IROCK registry is to evaluate oncological outcomes after delivery of SABR to primary kidney cancer. This will assist oncologists and future patients make evidence-based decisions about treatment options. Findings may also change the standard of care of patients for patients with RCC. The IROCK registry collects information about patient characteristics and medical history; clinical data relating to cancer diagnosis and staging; renal score and function; details of the SABR treatment administered; organ at risk and toxicity information; patterns of failure data and documentation of endpoints. Follow-up data is collected every 6 months after SABR.

The registry will also document novel combinations of systemic targeted agents and/or immunotherapies to establish their ability to enhance the effectiveness of the SABR technique. Given the projected increase in RCC globally, a better understanding of treatment options is pressing. The potential of SABR as a suitable treatment option for RCC in several patient cohorts therefore warrants further research, making the collection of data via a high quality, international, prospective registry essential.